tiprankstipranks
In this article:
Blurbs

Analysts’ Top Healthcare Picks: Biohaven Pharmaceutical Holding Co (BHVN), Adicet Bio (ACET)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biohaven Pharmaceutical Holding Co (BHVNResearch Report), Adicet Bio (ACETResearch Report) and Kazia Therapeutics (KZIAResearch Report) with bullish sentiments.

Biohaven Pharmaceutical Holding Co (BHVN)

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Biohaven Pharmaceutical Holding Co, with a price target of $160.00. The company’s shares closed last Monday at $100.24.

According to TipRanks.com, Tsao is a 4-star analyst with an average return of 7.7% and a 45.7% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Minerva Neurosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biohaven Pharmaceutical Holding Co with a $152.20 average price target, which is a 46.6% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $156.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Adicet Bio (ACET)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Adicet Bio today and set a price target of $34.00. The company’s shares closed last Monday at $13.57.

According to TipRanks.com, White is a 4-star analyst with an average return of 9.5% and a 35.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.

Adicet Bio has an analyst consensus of Strong Buy, with a price target consensus of $32.00, a 134.4% upside from current levels. In a report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $32.00 price target.

Kazia Therapeutics (KZIA)

In a report released today, Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Kazia Therapeutics, with a price target of $17.00. The company’s shares closed last Monday at $7.92, close to its 52-week low of $7.70.

According to TipRanks.com, CFA is a 2-star analyst with an average return of 2.4% and a 26.2% success rate. CFA covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, ThermoGenesis Holdings, and CASI Pharmaceuticals.

Currently, the analyst consensus on Kazia Therapeutics is a Moderate Buy with an average price target of $17.50, implying a 92.7% upside from current levels. In a report issued on December 3, Maxim Group also reiterated a Buy rating on the stock with a $18.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BHVN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed